Mitsubishi Tanabe Incurs 60 Billion-Plus Yen Operating Loss in 1st Half as Parkinson’s Program Lags

Mitsubishi Tanabe Pharma suffered an operating loss of over 60 billion yen in the April-September first half of FY2020 due to a delay in Israeli subsidiary NeuroDerm’s Parkinson’s project ND0612, which resulted in a write-down of nearly 85 billion yen...read more